Angioplasty/Atherectomy/Laser Therapy: Trapidil (Triazolopyrimidine), a Platelet-Derived Growth Factor Antagonist, Reduces Restenosis After Percutaneous Transluminal Coronary Angioplasty: Results of the Randomized, Double-Blind STARC Study - STARC


The Studio Trapidil versus Aspirin nella Restenosi Coronarica (STARC) was a multicenter, randomized, double-blind trial designed to assess the effects of trapidil in angiographic restenosis prevention after percutaneous transluminal coronary angioplasty (PTCA).